Icon Plc $ICLR is Hyperion Capital Advisors LP’s 8th Largest Position

Hyperion Capital Advisors LP increased its stake in shares of Icon Plc (NASDAQ:ICLR) by 34.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 66,021 shares of the medical research company’s stock after buying an additional 16,757 shares during the period. Icon accounts for approximately 5.9% of Hyperion Capital Advisors LP’s portfolio, making the stock its 8th largest holding. Hyperion Capital Advisors LP’s holdings in Icon were worth $12,030,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of ICLR. Toth Financial Advisory Corp purchased a new stake in shares of Icon in the 4th quarter valued at $27,000. Ameriflex Group Inc. purchased a new stake in shares of Icon in the 3rd quarter valued at $33,000. Johnson Financial Group Inc. purchased a new stake in shares of Icon in the 3rd quarter valued at $71,000. Quadrant Capital Group LLC purchased a new stake in shares of Icon in the 3rd quarter valued at $78,000. Finally, Wilmington Savings Fund Society FSB raised its holdings in shares of Icon by 198.8% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 487 shares of the medical research company’s stock valued at $89,000 after buying an additional 324 shares during the period. 95.61% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Robert W. Baird set a $119.00 price objective on Icon in a report on Friday, February 13th. Rothschild & Co Redburn set a $100.00 price objective on Icon and gave the company a “neutral” rating in a report on Tuesday, February 17th. BMO Capital Markets increased their target price on shares of Icon from $130.00 to $160.00 and gave the stock an “outperform” rating in a report on Friday, May 29th. JPMorgan Chase & Co. increased their target price on shares of Icon from $120.00 to $130.00 and gave the stock a “neutral” rating in a report on Friday, May 29th. Finally, Barclays increased their target price on shares of Icon from $120.00 to $150.00 and gave the stock an “equal weight” rating in a report on Friday, May 29th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Icon has a consensus rating of “Hold” and an average price target of $156.44.

Icon Price Performance

Icon stock opened at $146.18 on Friday. Icon Plc has a 52-week low of $66.57 and a 52-week high of $211.00. The company’s 50 day moving average is $121.76 and its two-hundred day moving average is $140.47. The firm has a market cap of $11.19 billion, a PE ratio of 23.73, a price-to-earnings-growth ratio of 11.84 and a beta of 1.26. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.31.

Icon (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, June 17th. The medical research company reported $2.52 earnings per share for the quarter, beating analysts’ consensus estimates of $2.47 by $0.05. Icon had a net margin of 5.98% and a return on equity of 9.50%. The business had revenue of $2.11 billion for the quarter, compared to analyst estimates of $1.99 billion. During the same period last year, the business earned $3.43 EPS. The company’s revenue was up 2.5% on a year-over-year basis. On average, research analysts expect that Icon Plc will post 9.74 EPS for the current fiscal year.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.